Fosamax Failure-To-Warn Claims Preempted, MDL Judge Rules
March 23, 2022
DOCUMENTS
- Order
TRENTON, N.J. — A New Jersey federal judge has ruled that state law failure-to-warn claims asserted in the Fosamax multidistrict litigation are preempted by federal law because the Food and Drug Administration rejected Merck’s proposed warning regarding bone fracture risks.
In a March 23 order, Judge of the U.S. District Court for the District of New Jersey explained that Merck proposed adding a “Low-Energy Femoral Shaft Fracture” warning to the “Precautions” section of the osteoporosis drug’s label, but the FDA remained unconvinced of a causal relationship between atypical femoral fractures and bisphosphonate drugs like Fosamax.
In the MDL, plaintiffs alleged …
UPCOMING CONFERENCES
![](https://harrismartin.s3.amazonaws.com/media/CACHE/images/uploads/conferences/iStock-115753557_fLooJhx/ebadaa70c9ae4eba2f27c08bcd68c09c.jpg)
HarrisMartin's Midwest Asbestos Litigation Conference
September 27, 2024 - St. Louis, MO
Four Seasons Hotel, St. Louis